OrbiMed takes point on a new biotech launch, but almost everything remains secret for now
If you missed the news of a new company launch backed by blue-chip investor OrbiMed early Wednesday morning, that was by design.
Alterome Therapeutics quietly emerged from stealth with $64 million in its Series A, a fairly large sum for an initial biotech raise. One would think, given the industry’s penchant for bombast, such a raise would be accompanied by all the fanfare that comes with an OrbiMed backing and enough cash to buy hundreds upon hundreds of the most expensive Tesla model.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.